Immune response to cyclin B1 in hepatocellular carcinoma

Giovanni Covini, Edward K L Chan, Mikio Nishioka, Syed Ahmed Morshed, Steven I. Reed, Eng M. Tan

Research output: Contribution to journalArticlepeer-review


Proteins expressed by plasmids encoding human cyclins and cyclin- dependent kinase 2 (CDK2) were used as antigens in immunoblotting. Fifteen of 100 patients with hepatocellular carcinoma (HCC) were found to have autoantibodies reactive with cyclin B1 and with a 40-kd degradation product of cyclin B1-glutathione-S-transferase (GST) fusion protein. Only one serum was found to react with cyclin A and another single serum with CDK2 but no antibodies were detected to cyclin D1 and E. The basis for autoimmune responses to cyclin B1 in HCC are unknown at the present time but the possibilities might include aberrations in cyclin B1 regulation leading to altered product or its expression which resulted in stimulation of immune reactions.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
Issue number1
Publication statusPublished - Jan 1997

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'Immune response to cyclin B1 in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this